Koya Medical, Inc.

Koya Medical is a medical device company founded in 2018 and headquartered in Dallas, TX, with advanced research operations in Oakland, CA. The company specializes in innovative therapeutic solutions for chronic venous and lymphatic disease management. Koya's primary product is Dayspring, a non-pneumatic compression device for lymphedema and phlebolymphedema treatment that has demonstrated superior clinical outcomes compared to pneumatic compression systems. The Dayspring platform demonstrated 4x more edema reduction and 44% higher treatment adherence versus pneumatic compression in the multi-center, randomized TEAYS trial published in the Journal of Vascular Surgery, with significant improvements in patient quality of life. The company also offers TissueIQ for lymphedema assessment, K9 for chronic venous insufficiency, and K1 for deep vein thrombosis and chronic occlusions. Koya serves healthcare professionals, patients, caregivers, and the VA/military community. The organization has treated over 14,950 patients and maintains 100+ associates. Leadership includes CEO and Founder Andy Doraiswamy, PhD (previously developed sight-restoring implants). The company provides clinical evidence-based support, professional education, reimbursement guidance, and patient support resources. Koya's mission centers on redefining vascular health through solutions addressing unmet needs across the venous and lymphatic disease continuum, with a focus on improving patient outcomes, experience, and access to care.